Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Sophia Antipolis, 29 September 2020:
The European Society of Cardiology would like to emphasise that the research on the effects of hydroxychloroquine on arrhythmias published recently by Gasperetti et al in EP Europace, a journal of the European Society of Cardiology (ESC),1 was not designed to test the effectiveness of hydroxychloroquine in COVID-19 but only to assess safety with respect to electrocardiogram (ECG) changes and heart rhythm.
In this study, short-term hydroxychloroquine treatment was not associated with severe cardiac rhythm disorders in patients with COVID-19 under appropriate surveillance, which included screening of the patients´ ECG prior to initiating the drug and repeat ECGs during the course of treatment. The study does not provide any evidence that hydroxychloroquine will contribute to the cure of COVID-19.
The Europace paper is here: Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.
The press release is here: Heart rhythm in COVID-19 patients receiving short term treatment with hydroxychloroquine.
Authors: ESC Press OfficeTel: +33 (0)4 89 87 20 85
Mobile: +33 (0)7 8531 2036Email: firstname.lastname@example.org
Follow us on Twitter @ESCardioNews
1Gasperetti A, Biffi M, Duru F, et al. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. Europace. 2020. doi:10.1093/europace/euaa216.
About the European Society of Cardiology
The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.
About EP Europace
EP Europace covers the fields of arrhythmias, pacing and cellular electrophysiology.
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.